FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295311> ?p ?o ?g. }

• W4286295311 endingPage "e20024" @default.
• W4286295311 startingPage "e20024" @default.
• W4286295311 abstract "e20024 Background: Maintenance therapy with single-agent lenalidomide (Len) after autologous hematopoietic stem cell transplantation (autoHCT) for multiple myeloma (MM) is associated with improved progression-free survival (PFS). However, patients with high-risk chromosomal abnormalities may need a more intense regimen. We hypothesized that adding another anti-myeloma drug to Len would lead to improved outcomes. Methods: We conducted a retrospective single-center chart review of adult MM patients with high risk cytogenetic abnormalities that received autoHCT between 2008-2018, followed by Len-based maintenance therapy. High risk cytogenetics were defined as del17p, t(4;14), t(14;16), 1q21 gain or amplification by fluorescence in situ hybridization. We divided patients into those who received either single-agent Len maintenance (Len-only) or Len-based combinations (Len-combo). We compared PFS, overall survival (OS), non-relapse mortality (NRM), day 100 and best post-transplant responses, and minimal residual disease (MRD) status between groups. We performed sensitivity analyses using inverse probability weights to correct for potential bias due to nonrandomization of the two groups. Results: A total of 231 patients with HRMM were included in our analysis, with a median age of 62.4 (range 33.5-79.9) years, and 55% were male. There were 153 patients in the Len-only group and 78 in the Len-combo group. Len-combo regimens were either doublets (Len with dexamethasone [dex: n = 10], elotuzumab [n = 28] or ixazomib [n = 14]) or triplets (Len with bortezomib/dex [n = 10], ixazomib/dex [n = 10] or carfilzomib/dex [n = 6]). More patients in the Len-combo group had >2 high risk cytogenetic abnormalities compared to the Len-only group (32% vs. 12%: p < 0.001). Busulfan + melphalan (Bu-Mel) conditioning was used in 12% vs. 18% in Len-only vs. Len-combo groups (p = 0.32). The final best response post-transplant of sCR/CR was 50% in the Len-only group vs. 54% in the Len-combo group (p = 0.72). Median follow up was 40.7 and 35.3 months, with Len-only and Len-combo, respectively. Median PFS and OS for all patients were 25.5 and 82.6 months, respectively. There was no significant difference in PFS (HR: 1.01, CI: 0.71-1.44, p = 0.94) or OS (HR: 0.84, CI: 0.49-1.43, p = 0.52) between groups. Similarly, there was no difference in outcomes between the groups whether they received conditioning with melphalan-only or Bu-Mel. However, for patients with HR cytogenetic abnormalities other than 1q+ there was a trend towards better PFS with Len-combo (HR 0.59, CI 0.32-1.09, p = 0.09), without a difference in OS (HR: 0.79, CI: 0.37-1.65, p = 0.53). Conclusions: In this single center retrospective analysis, intensification of post-transplant Len maintenance did not show an improvement in outcomes for HRMM patients. However, there was a trend towards improved PFS in patients with HR abnormalities other than 1q+." @default.
• W4286295311 created "2022-07-21" @default.
• W4286295311 creator A5008785159 @default.
• W4286295311 creator A5015342719 @default.
• W4286295311 creator A5016260142 @default.
• W4286295311 creator A5022871468 @default.
• W4286295311 creator A5029237145 @default.
• W4286295311 creator A5037077714 @default.
• W4286295311 creator A5037963602 @default.
• W4286295311 creator A5038235561 @default.
• W4286295311 creator A5038619722 @default.
• W4286295311 creator A5048362577 @default.
• W4286295311 creator A5048913229 @default.
• W4286295311 creator A5055885795 @default.
• W4286295311 creator A5055929208 @default.
• W4286295311 creator A5060313982 @default.
• W4286295311 creator A5068834306 @default.
• W4286295311 creator A5069460930 @default.
• W4286295311 creator A5069676375 @default.
• W4286295311 creator A5071516639 @default.
• W4286295311 date "2022-06-01" @default.
• W4286295311 modified "2023-09-23" @default.
• W4286295311 title "Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma." @default.
• W4286295311 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e20024" @default.
• W4286295311 hasPublicationYear "2022" @default.
• W4286295311 type Work @default.
• W4286295311 citedByCount "0" @default.
• W4286295311 crossrefType "journal-article" @default.
• W4286295311 hasAuthorship W4286295311A5008785159 @default.
• W4286295311 hasAuthorship W4286295311A5015342719 @default.
• W4286295311 hasAuthorship W4286295311A5016260142 @default.
• W4286295311 hasAuthorship W4286295311A5022871468 @default.
• W4286295311 hasAuthorship W4286295311A5029237145 @default.
• W4286295311 hasAuthorship W4286295311A5037077714 @default.
• W4286295311 hasAuthorship W4286295311A5037963602 @default.
• W4286295311 hasAuthorship W4286295311A5038235561 @default.
• W4286295311 hasAuthorship W4286295311A5038619722 @default.
• W4286295311 hasAuthorship W4286295311A5048362577 @default.
• W4286295311 hasAuthorship W4286295311A5048913229 @default.
• W4286295311 hasAuthorship W4286295311A5055885795 @default.
• W4286295311 hasAuthorship W4286295311A5055929208 @default.
• W4286295311 hasAuthorship W4286295311A5060313982 @default.
• W4286295311 hasAuthorship W4286295311A5068834306 @default.
• W4286295311 hasAuthorship W4286295311A5069460930 @default.
• W4286295311 hasAuthorship W4286295311A5069676375 @default.
• W4286295311 hasAuthorship W4286295311A5071516639 @default.
• W4286295311 hasConcept C126322002 @default.
• W4286295311 hasConcept C141071460 @default.
• W4286295311 hasConcept C143998085 @default.
• W4286295311 hasConcept C207103383 @default.
• W4286295311 hasConcept C2776063141 @default.
• W4286295311 hasConcept C2776364478 @default.
• W4286295311 hasConcept C2776694085 @default.
• W4286295311 hasConcept C2777408962 @default.
• W4286295311 hasConcept C2777478702 @default.
• W4286295311 hasConcept C2778283404 @default.
• W4286295311 hasConcept C2778524551 @default.
• W4286295311 hasConcept C2779050716 @default.
• W4286295311 hasConcept C2779823535 @default.
• W4286295311 hasConcept C2780007613 @default.
• W4286295311 hasConcept C2780108899 @default.
• W4286295311 hasConcept C2780739268 @default.
• W4286295311 hasConcept C2781098529 @default.
• W4286295311 hasConcept C2781413609 @default.
• W4286295311 hasConcept C2911091166 @default.
• W4286295311 hasConcept C44249647 @default.
• W4286295311 hasConcept C71924100 @default.
• W4286295311 hasConceptScore W4286295311C126322002 @default.
• W4286295311 hasConceptScore W4286295311C141071460 @default.
• W4286295311 hasConceptScore W4286295311C143998085 @default.
• W4286295311 hasConceptScore W4286295311C207103383 @default.
• W4286295311 hasConceptScore W4286295311C2776063141 @default.
• W4286295311 hasConceptScore W4286295311C2776364478 @default.
• W4286295311 hasConceptScore W4286295311C2776694085 @default.
• W4286295311 hasConceptScore W4286295311C2777408962 @default.
• W4286295311 hasConceptScore W4286295311C2777478702 @default.
• W4286295311 hasConceptScore W4286295311C2778283404 @default.
• W4286295311 hasConceptScore W4286295311C2778524551 @default.
• W4286295311 hasConceptScore W4286295311C2779050716 @default.
• W4286295311 hasConceptScore W4286295311C2779823535 @default.
• W4286295311 hasConceptScore W4286295311C2780007613 @default.
• W4286295311 hasConceptScore W4286295311C2780108899 @default.
• W4286295311 hasConceptScore W4286295311C2780739268 @default.
• W4286295311 hasConceptScore W4286295311C2781098529 @default.
• W4286295311 hasConceptScore W4286295311C2781413609 @default.
• W4286295311 hasConceptScore W4286295311C2911091166 @default.
• W4286295311 hasConceptScore W4286295311C44249647 @default.
• W4286295311 hasConceptScore W4286295311C71924100 @default.
• W4286295311 hasIssue "16_suppl" @default.
• W4286295311 hasLocation W42862953111 @default.
• W4286295311 hasOpenAccess W4286295311 @default.
• W4286295311 hasPrimaryLocation W42862953111 @default.
• W4286295311 hasRelatedWork W2016202982 @default.
• W4286295311 hasRelatedWork W2056322049 @default.
• W4286295311 hasRelatedWork W2109013784 @default.
• W4286295311 hasRelatedWork W2284666263 @default.
• W4286295311 hasRelatedWork W2344741804 @default.
• W4286295311 hasRelatedWork W2478188943 @default.

• next